A 68-year-old man is evaluated for progressive shortness of breath, fatigue, and bilateral… — USMLE Step 2 CK

A $68$ -year-old man is evaluated for progressive shortness of breath, fatigue, and bilateral lower extremity swelling over the past $6$ months. He also reports numbness and tingling in both hands, for which he underwent bilateral carpal tunnel release surgery last year. Blood pressure is $110/70 \text{ mmHg}$ , and pulse is $85 \text{ /min}$ . Physical examination reveals elevated jugular venous pressure with prominent x and y descents, clear lungs, and $2+$ pitting edema in the lower extremities. An electrocardiogram shows low voltage in the limb leads. A transthoracic echocardiogram demonstrates severe left ventricular concentric thickening, a granular "sparkling" appearance of the myocardium, biatrial enlargement, and a preserved left ventricular ejection fraction of $60\%$ . A diagnosis of cardiac amyloidosis is suspected.

Arrange the following diagnostic and management steps in the most appropriate chronological sequence for evaluating and treating this patient's condition.

1Perform serum free light chain assay and protein electrophoresis with immunofixation
2Perform technetium-99m pyrophosphate (Tc-99m PYP) cardiac scintigraphy
3Obtain genetic testing for transthyretin (TTR) gene sequencing
4Initiate targeted pharmacotherapy with a transthyretin stabilizer (e.g., tafamidis)

Cevap

The correct sequence is: (1) Perform serum free light chain assay and protein electrophoresis with immunofixation, (2) Perform technetium-99m pyrophosphate (Tc-99m PYP) cardiac scintigraphy, (3) Obtain genetic testing for transthyretin (TTR) gene sequencing, and (4) Initiate targeted pharmacotherapy with a transthyretin stabilizer.

The standard diagnostic algorithm for cardiac amyloidosis demands a strict sequence to avoid misdiagnosis and delayed treatment of fatal conditions. AL amyloidosis must be ruled out first with monoclonal protein screening. If negative, ATTR amyloidosis is confirmed with a Tc-99m PYP scan. Once ATTR is confirmed, genetic testing determines if it is hereditary or wild-type. Finally, disease-modifying therapy like tafamidis is initiated.

Adım Adım Çözüm

Identify the underlying clinical syndrome and its potential variants.

The patient's presentation is highly suspicious for cardiac amyloidosis. The two main systemic forms that affect the heart are light chain (AL) amyloidosis and transthyretin (ATTR) amyloidosis.

Differentiating these subtypes is critical because their management and prognoses are entirely different.

Select the most critical initial diagnostic test to rule out the most life-threatening subtype.

A monoclonal protein screen (serum free light chains, and serum/urine protein electrophoresis with immunofixation) must be performed first.

Excluding AL amyloidosis is the highest priority because it is a hematological malignancy that requires urgent chemotherapy. Furthermore, subsequent non-invasive scans can have false positives if AL amyloidosis is not excluded first.

Determine the next diagnostic step assuming the monoclonal protein screen is negative.

Technetium-99m pyrophosphate (Tc-99m PYP) cardiac scintigraphy is performed.

In the absence of a monoclonal protein, strong myocardial uptake on a Tc-99m PYP scan confirms the diagnosis of ATTR cardiac amyloidosis non-invasively, sparing the patient from a high-risk endomyocardial biopsy.

Determine the required follow-up testing once ATTR amyloidosis is confirmed.

Genetic testing for the transthyretin (TTR) gene must be obtained.

ATTR amyloidosis can be either wild-type (senile/age-related) or variant (hereditary). Genetic testing distinguishes between these two, which is essential to determine if family members require genetic counseling and screening.

Select the definitive management strategy for the confirmed condition.

Initiate targeted pharmacotherapy with a transthyretin stabilizer (e.g., tafamidis).

Once the precise diagnosis and genetic subtype are established, tafamidis is used to prevent the dissociation of the TTR tetramer, thereby reducing mortality and cardiovascular hospitalizations.

Anahtar Kavram

The diagnostic algorithm for suspected cardiac amyloidosis requires prioritizing the exclusion of AL amyloidosis (via monoclonal protein screening) before confirming ATTR amyloidosis non-invasively (via Tc-99m PYP scintigraphy) and proceeding to genetic testing.

Soru

Cevap

Adım Adım Çözüm

Anahtar Kavram

Sık Yapılan Hatalar

Konular

Bu konudan daha fazla soru